Immune-focused machine learning firm joins leading AI cohort on Park
Etcembly Ltd has moved into more than 1,000 square feet of new laboratory and office premises within The Oxford Science Park (TOSP). It is the latest company to establish a base at TOSP which has a strong AI cohort and is one of the UK's leading parks for science and technology companies.
Etcembly recently closed an oversubscribed seed round with private investors, and is looking to hire talented scientists and data engineers to develop further its machine learning platform EMLy™ . The technology is expected to accelerate the discovery of novel immunotherapies for a range of diseases.
The founders and management team of Etcembly, Dr Michelle Teng, CEO, and Dr Jacob Hurst, CTO, have a unique blend of machine learning and immunology expertise. The company recently signed an exclusive research collaboration with Zelluna Immunotherapy.
Etcembly joins a group of thriving companies which use artificial intelligence techniques in their research. This includes Exscientia, using AI to precision engineer future drugs for patients and revolutionise drug discovery, MoA Technology, which is focused on the development of novel herbicides with positive environmental and economic impact, and Sensyme Health, which is applying clinical AI in health and life sciences.
Michelle Teng, CEO of Etcembly, said
"Our new laboratory and office facilities allow us to continue the company's ambitious development plans following our recent fundraising and collaboration deal. We expect to thrive in The Oxford Science Park's environment of innovation and entrepreneurship."
Rory Maw, Bursar of Magdalen College & Interim MD of TOSP, said,
"We are delighted to see such an exciting company expanding here on the Park. Etcembly's approach has great potential, and we expect it to have major impact on health, alongside the other companies in the AI cohort at The Oxford Science Park."
About Etcembly Limited
Etcembly is a privately owned, Oxfordshire-based company. Its mission is to decode immune repertoires in health and disease by building a pioneering machine learning platform (EMLy™). EMLy™ will be the world’s leading health and disease immune database, to fulfil the vision of lean drug discovery for immunotherapy and personalised therapeutics across all patient groups globally.
About The Oxford Science Park
The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College’s heritage and provides one of the most influential science & technology environments in the UK. There is approaching 750,000 square feet of workspace accommodation across the Park, which is now home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Sciences Innovation, Evox Therapeutics, Vaccitech, Exscientia, Sensyne Health and Intuitive Surgical.
In addition to being a key property investment, the Park is at the heart of Magdalen College's strategy to support discovery, innovation and entrepreneurship. It will continue to develop The Oxford Science Park as a long-term strategic asset, with ambitious plans to create an additional 500,000+ sq ft of office and laboratory space on the remaining 12 acres of land over the next 3-5 years. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park’s exceptional environment and collegiate and collaborative ethos. The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City’s southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services.
Forward Looking Statement
While Etcembly believes any forward-looking statements in this press release are accurate, the statements represent Etcembly’s beliefs only as of the date of this press release. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Etcembly undertake no intent or obligation to update the information contained in this press release as new information becomes available.